Life Biosciences (Boston, USA) has initiated the first human trial of partial cellular reprogramming using three Yamanaka factors (OSK) delivered via viral vector to the eye. The trial targets glaucoma and NAION (sudden vision loss). Early safety data are expected within 12 months. This is the first time epigenetic age reversal has been attempted in humans outside of a laboratory setting.
University of California, Irvine (USA) reported that SSK1, a gemcitabine prodrug activated only in senescent cells, reduced p16+ senescent cells by ~45% in a mouse model of temporal lobe epilepsy. 60% of treated animals became seizure‑free, with no apparent neurotoxicity. This represents a new class of targeted senolytic with fewer off‑target effects.
Chinese Academy of Sciences (Beijing) used gene‑edited stem cells to restore cognitive function and reduce senescent cell burden across ten physiological systems in aged rhesus macaques. The study provides the first primate evidence that systemic senolytic + regenerative therapy may reverse multiple hallmarks of aging.
Niigata University (Japan) identified DEL‑1 as a protein that may clear senescent cells naturally. In mouse models, DEL‑1 prevented age‑related bone loss. The authors propose it as the first known endogenous senolytic, though independent replication is still needed.
St. Petersburg Institute of Bioregulation (Russia) published a small human study (n=40) suggesting that 10 years of periodic Epitalon use was associated with longer telomeres and lower inflammatory markers. Independent replication is lacking, and the study was not placebo‑controlled. We include it here for completeness, with the caveat that these claims require independent validation.